Want to see AU:PTX full AI Analyst Report?
Prescient Therapeutics Limited (PTX) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Ptx-100 | Ctcl | Phase II | Recruiting | A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL | Feb 18, 2025 | ― |
| Ptx-100 | Advanced Cancer, Ptcl | Phase I | Completed | Phase 1 Study of PTX-100 in Patients With Advanced Malignancies With PTCL Expansion Cohort | Mar 13, 2019 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Ptx-100 | Phase II | Ctcl | Recruiting | A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL | Feb 18, 2025 | ― |
| Ptx-100 | Phase I | Advanced Cancer, Ptcl | Completed | Phase 1 Study of PTX-100 in Patients With Advanced Malignancies With PTCL Expansion Cohort | Mar 13, 2019 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Prescient Therapeutics Limited (AU:PTX) have in its pipeline
Prescient Therapeutics Limited AU:PTX is currently developing the following drugs: Ptx-100. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
